Print Page  Close Window

SEC Filings

VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document

Table of Contents

    no exercise by the underwriters of their option to purchase up to                        additional shares of common stock from us;
    the conversion of all outstanding shares of our convertible preferred stock into 218,309,741 shares of our common stock, which is expected to occur immediately prior to consummation of this offering, either through satisfaction of the conditions for automatic conversion, based on the aggregate proceeds of this offering, or with the consent of the required preferred stockholders, which we refer to as the automatic preferred stock conversion; and
    a 1-for-            reverse split of our common stock prior to the effectiveness of the registration statement of which this prospectus forms a part.